5 Rheumatology Headlines You Missed in February 2026

February's rheumatology news reflected a field in motion on multiple fronts—regulatory, clinical, and editorial, with the 2026 Rheumatology Winter Clinical Symposium earmarking the month. Ianalumab's Breakthrough Therapy designation for Sjögren disease marked a long-overdue signal of progress in a condition that has never had a targeted, FDA-approved treatment, while Thomas Grader-Beck, MD, offered a grounded perspective on what the NEPTUNUS data actually show and where cautious optimism is warranted. RA Awareness Day served as an occasion to look beyond the pipeline, with experts reminding clinicians that pharmacologic control of inflammation remains an incomplete answer for many patients, and that nonpharmacologic approaches continue to lag in research investment. On the practical side, Eric Ruderman, MD, articulated the growing clinical reality of GLP-1 receptor agonists entering the rheumatology conversation—not as primary therapy, but as adjuncts whose effects on disease activity may run deeper than weight loss alone. Anisha Dua, MD, MPH, meanwhile, brought welcome nuance to a conversation about updated vasculitis classification criteria, clarifying what they are designed to do and where the real diagnostic and prognostic gaps persist. And with the launch of Joint Ventures, RheumatologyLive introduced a new podcast format built for clinicians who want to sit with complexity rather than sidestep it.

Check out this February 2026 rheumatology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

1. Rheumatoid Arthritis Awareness Day: Gaps Remain Despite Therapeutic Advances

In recognition of RA Awareness Day, RheumatologyLive examined both the substantial therapeutic progress made over the past two decades and the persistent gaps that continue to burden patients, with experts underscoring that persistent pain, weakness, and functional impairment can remain even when inflammation is pharmacologically controlled. The conversation highlighted the relative underinvestment in nonpharmacologic approaches—physical therapy, exercise, and lifestyle interventions—despite their recognized importance as complements to disease-modifying therapy. Together, the perspectives offered underscore that advancing RA care will require not just new drugs, but better personalization of existing treatments and a broader framework for long-term disease management.

2. Breakthrough Therapy Ianalumab Efficacious, Safe for Sjögren Disease, With Thomas Grader-Beck, MD

RheumatologyLive spoke with Thomas Grader-Beck, MD, associate professor of clinical medicine at Johns Hopkins University of Medicine and a NEPTUNUS trial investigator, who noted that ianalumab's FDA Breakthrough Therapy designation reflects both the robustness of the phase 3 data and the magnitude of unmet need in Sjögren disease—where no targeted therapies currently exist. Grader-Beck highlighted the dual mechanism of ianalumab, which combines B-cell depletion via enhanced antibody-dependent cellular cytotoxicity with BAFF-R blockade, as a potentially meaningful advance over prior B-cell-directed approaches that targeted only one of those pathways. He also noted the consistency of the efficacy signal across both NEPTUNUS trials and multiple outcome domains—including physician- and patient-reported measures—as particularly encouraging, with Novartis planning to submit regulatory applications globally in early 2026.

3. Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS

RheumatologyLive launched Joint Ventures, a new podcast hosted by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 UK-based rheumatologists who will examine emerging evidence, new mechanisms of action, and shifting paradigms in rheumatology, with a focus on how developments in the field intersect with clinical reasoning and long-term patient management. The series is designed for rheumatologists and clinicians navigating an increasingly complex therapeutic landscape, aiming to bridge the gap between rapidly evolving science and real-world practice. Each episode will take on the kind of nuanced clinical and scientific questions that rarely fit neatly into a conference abstract or news brief.

4. Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD, MPH

Anisha Dua, MD, MPH, professor at Northwestern University Feinberg School of Medicine and director of the Vasculitis Center, discussed whether updated vasculitis classification criteria—the first revisions since 1990—have meaningfully changed clinical practice, emphasizing that these criteria are designed primarily to standardize patient populations for clinical trials rather than serve as strict diagnostic tools at the bedside. She noted that the newer systems represent a major step forward by incorporating advances in pathophysiology, imaging, and biomarker science through weighted scoring rather than simple checkbox thresholds, better reflecting the complexity seen in clinical settings. Still, she identified the most pressing unmet needs as extending beyond classification: identifying which patients face the highest risk for severe disease and determining which subgroups respond best to specific targeted therapies remain open questions the field has yet to resolve.

5. GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, With Eric Ruderman, MD

Eric Ruderman, MD, professor of rheumatology at Northwestern University Feinberg School of Medicine, discussed how the rising use of GLP-1 receptor agonists has brought metabolic and cardiovascular health to the forefront of rheumatology care, with clinicians increasingly attending to the interplay between systemic inflammation, obesity, and cardiometabolic comorbidities—particularly in PsA, where overlapping psoriasis, axial involvement, and metabolic syndrome frequently coexist. Ruderman noted that treatment selection in these patients must account for multiple organ systems simultaneously, and that certain therapies may benefit several domains while others require caution depending on coexisting gut involvement or axial disease. He expressed particular interest in GLP-1 agents as potential adjuncts to standard therapy, citing patient reports of meaningful improvement beyond what would be expected from weight loss alone, and anticipating that more robust data on their role in rheumatic disease will emerge over the next 1 to 2 years.